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R
NAi-based therapy continues to be
one of the most promising concepts
for the treatment of several diseases,
especially cancer. Although the biological
process of gene silencing is understood in
its details, thus enabling the design of very
efficient and safe synthetic siRNA molecules,
the main challenge in this field remains
delivery. The nucleic acid has to overcome
many hurdles when injected locally or in-
travenously. Crucial steps such as stability
and protection in the extracellular environ-
ment, recognition of the target cell, over-
coming the barrier of cellular membranes,
and entrance into the cytosol remain chal-
lenging bottlenecks in the delivery pro-
cess.15 As viral carriers are still subject to
safety concerns, especially for systemic de-
livery, synthetic structures have been devel-
oped to overcome limitations in the delivery
process. In addition to liposomes and lipo-
plexes, polycations represent an important
group of molecules showing encouraging
potential as carrier systems.611 Although
classical cationic polymers such as polyethy-
lenimine (PEI) have shown the ability to
transport nucleic acids, they still lack effi-
ciency compared to their viral counterparts.
Thus functional substructures, addressing
key limitations in the delivery process, have
been incorporated into these polymers by
chemical conjugation. For the reduction of
interactions with blood compounds and an
increased polyplex stability, poly(ethylene
glycol) (PEG) was coupled to the poly-
cations.10,1216 PEG is known to increase
solubility and to efficiently shield attached
molecules. Targeting ligands for overex-
pressed cell surface receptors were incorpo-
rated for preferential transfection of the
intended tissue.10,14,17 As a further crucial
step during the delivery process, the endo-
somal escape ability of polymeric carriers
has been improved by addition of lytic
peptides. For example, acidic peptide ana-
logues based on the amino terminus of the
influenza virus hemagglutinin (HA-2)18,19 or
masked mellitin derivatives16,20 were used,
strongly boosting the activity of weakly
effective polymers such as polylysine for
pDNA and siRNA delivery. Furthermore, such
conjugated polymers became biorespon-
sive, reacting to pH changes in the endo-
somal microenvironment. Despite great ad-
vances in the field, the high complexity of
these new generations of polycationic poly-
mers led to quite heterogenic, polydisperse
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ABSTRACT Although our understanding of RNAi and
our knowledge on designing and synthesizing active and
safe siRNAs significantly increased during the past
decade, targeted delivery remains the major limitation
in the development of siRNA therapeutics. On one hand,
practical considerations dictate robust chemistry reproducibly providing precise carrier
molecules. On the other hand, the multistep delivery process requires dynamic multifunctional
carriers of substantial complexity. We present a monodisperse and multifunctional carrier
system, synthesized by solid phase supported chemistry, for siRNA delivery in vitro and in vivo.
The sequence-defined assembly includes a precise cationic (oligoethanamino)amide core,
terminated at the ends by two cysteines for bioreversible polyplex stabilization, at a defined
central position attached to a monodisperse polyethylene glycol chain coupled to a terminal
folic acid as cell targeting ligand. Complexation with an endosomolytic influenza peptide-
siRNA conjugate results in nanosized functional polyplexes of 6 nm hydrodynamic diameter.
The necessity of each functional substructure of the carrier system for a specific and efficient
gene silencing was confirmed. The nanosized polyplexes showed stability in vivo, receptor-
specific cell targeting, and silencing of the EG5 gene in receptor-positive tumors. The nanosized
appearance of these particles can be precisely controlled by the oligomer design (from 5.8 to
8.8 nm diameter). A complete surface charge shielding together with the high stability result
in good tolerability in vivo and the absence of accumulation in nontargeted tissues such as
liver, lung, or spleen. Due to their small size, siRNA polyplexes are efficiently cleared by the
kidney.
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structures. Reproducibility, purification, analytics, and a
clear structureactivity relationship remain extremely
difficult to achieve. As an additional complication, the
formed polyplexes often are very polydisperse and
large in size, presenting nanoparticle mixtures includ-
ing polyplex aggregates. Small monomolecular com-
plexes have been reported,2124 however they often
lack functional activity.
Recent studies generated libraries of molecularly
defined polycationic structures,2528 which reveal the
benefit of precise carriers with clear structureactivity
relationships. In the current work we extend this
strategy by incorporating functional targeting, shield-
ing, and endosomolytic domains into siRNA polyplexes
in a highly defined fashion.
Persuing the concept described in Schaffert et al.,2729
we generated a nonpeptidic cationic backbone com-
posed of (oligoethanamino)amide structures by solid
phase supported (SPS) synthesis. SPS is continued by
attachment of a monodisperse poly(ethylene glycol)
chain at a defined position followed by regioselective
coupling of folic acid as ligand for specific cell target-
ing. To increase the endosomal escape ability of the
delivery system, Inf7 as an endosomolytic peptide was
coupled to the 50-end of the siRNA sense strand. Thus,
in contrast to conventional polymer conjugate synthe-
ses, the current design enables the synthesis of a
molecularly precise product with beneficial delivery
properties. We show the efficient synthesis and pur-
ification of thesemolecules, including a qualitative and
quantitative analysis of the products. Functionality and
necessity of every single substructure could be demon-
strated separately, showing synergism on the siRNA
silencing effect in vitro. Importantly, PEG-shielded un-
imolecular siRNA nanoparticles with a hydrodynamic
diameter of only 5.8 nm and a neutral zeta poten-
tial were formed. Treatment of mice bearing sub-
cutaneous tumors expressing the folic acid receptor
showed that the targeted nanosized particles have an
increased retention in the tumor tissue, resulting in a
clear silencing effect without cross reactivity to other
tissues.
RESULTS AND DISCUSSION
Design and Synthesis of the Defined Folic Acid Targeted
Polycation. As a model system for our modular assem-
bly strategy, we chose a structure for complexing
siRNA, composed of eight artificial succinoyl tetraethy-
lene pentamine (Stp) building blocks (Figure 1a) as a
polycationic backbone containing 40 nitrogens, of
which 24 are protonatable. The remaining 16 nitrogens
are engaged in amide bond formation. In order to
increase siRNA polyplex stability, cysteines were incor-
porated at the C- and N-terminus of the peptide-like
polycation, enabling the formation of disulfide bonds
during polyplex formation. A monodisperse, commer-
cially available heterobifunctional polyethylene glycol
chain (Fmoc-N-amido-dPEG24-acid, QuantaBiodesign,
OH, USA) was introduced into the oligomer chain at a
defined position using lysine as a branching point
Figure 1. Synthesis and characterization of the folic acid targeted, defined polycation 356. (a) Scheme of synthesis on solid
support. (b) Chromatogram of an analytical RP-HPLC run of the cleaved, deprotected, lyophilized polycation. (c) MALDI-TOF-
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(Figure 1a). The PEG chainwas extended by coupling of
glutamic acid followed by pteroic acid, resulting in a
folate ligand as targeting structure. As it is known that
the coupling of folic acid via itsR-carboxy group results
in a reduced binding affinity to its receptor, the cou-
pling was performed via its γ-carboxy group.30 Purity
and identity of the synthesized structure FolA-PEG24-
K(Stp4-C)2 (356) was demonstrated by analytical
RP-HPLC (Figure 1b), MALDI-TOF-MS analysis (Figure 1c),
and 1H NMR (Figure S1a). Controls lacking the target-
ing ligand (188) or its cysteines (420) were synthe-
sized persuing analogous procedures (for analysis see
Figures S1b and S2). Functional analogueswith precise,
longer PEG spacers, FolA-PEG48-K(Stp4-C)2 (482) and
FolA-PEG72-K(Stp4-C)2 (483), are described in the Sup-
porting Information (Figure S14).
Design and Synthesis of the Endosomolytic Active siRNA
Influenza Peptide Conjugate. As the targeted polycationic
peptide includes functional substructures for siRNA
binding, polyplex stability, and folate receptor target-
ing, endosomal escape is the remaining critical bottle-
neck. Most reported concepts used lytic peptides
covalently attached to the polymeric carrier,16,19 which
bears some risk of dissociation from the siRNA before
cellular uptake. In this study the lytic peptide was
coupled to the siRNA's backbone to ensure endosomal
co-localization. Inf7, an acidic peptide analogue of the
amino terminus of the influenza virus hemagglutinin,
was chosen due to its overall negative charge and
reported pH-dependent lytic activity.18 The peptide
was covalently conjugated to the 50-end of the siRNA's
sense strand to maintain the silencing efficiency. As
shown in Figure 2a, the conjugate was prepared by
activation of the siRNA's thiol group and subsequent
reaction of the peptide's C-terminal cysteine. After
purification of the conjugate by strong anion exchange
chromatography (Figure 2b) the product was analyzed
by agarose gel electrophoresis (Figure 2c). Fractions
containing retarded siRNA compared to unconjugated
input siRNA (fractions 58) were pooled and analyzed
by MALDI-TOF-MS (Figure S3).
Functionality and Necessity of Substructures. Concepts
including different substructures using common syn-
thesis strategies are often limited in showing the
beneficial effect of the incorporated substructures,
due to very complex synthesis protocols. In this study
we developed a system enabling a clear structure
activity relationship, minimizing the carrier to highly
functionalized, necessary components for successful
siRNA delivery. For siRNA binding the polycationic
backbone consisting of eight Stp units was designed.
Schaffert et al. already showed that Stp-bearing struc-
tures bind nucleic acids very efficiently when cross-
linked via disulfide bonds.27 Thus cysteines were
incorporated to enhance polyplex stability. The stabi-
lizing effect is shown in a gel shift assay (Figure 3a),
comparing the functional oligomer 356 with the ana-
logue 420, bearing serines instead of cysteines. Data
clearly show that an oligomer protonatable nitrogen/
siRNA phosphate (N/P) ratio of 6 leads to efficient
siRNA binding, hampering its migration in the agarose
gel in case of cysteine-bearing oligomer 356. Without
cross-linking ability (420), the binding is weaker and
the payload is released from the carrier. This reveals
that the combination of the polycationic backbone and
cysteines results in efficient siRNA binding. A detailed
analysis of polycation to siRNA binding revealed that
an N/P ratio of 3 is sufficient for siRNA retardation
(Figure S4), which is in good agreement with titration
experiments of free oligomer, giving a protonation
Figure 2. Synthesis and characterization of the influenza peptidesiRNA conjugate. (a) Synthesis scheme. The resulting
conjugate was purified via strong anion exchange chromatography. (b) Chromatogram of the siRNA-Inf7 conjugate
purification using a ResourceQ column (1 mL, GE Healthcare) connected to an Äkta basic system, detection at 260 nm.
118: Collected fractions for analysis. (c) Analytical agarose gel electrophoresis of HPLC fractions. The 0.5 mL fractions were
collected during conjugate purification. Fractions 58 containing siRNA with altered electrophoretic mobility compared to
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state of protonatable amines of 47%at pH 7.4 (Figure S5).
Thus particles are formed until charge neutralization.
Additional oligomer that was added after particle
saturation stays free in solution, as demonstrated by
a separate gel shift assay using Alexa488-labeled oli-
gomer 583 in combination with siRNA-Inf7 (Figure S6).
Disulfide exchange reactions between the siRNA-Inf7
disulfides and the added thiols of the polycation
during polyplex formation would be a theoretical but
unlikely possibility; as can be seen in Figure S7, disul-
fide exchange did not take place upon incubation of
siRNA-Inf7 with free cysteine at the same doses as in
polyplex formations. To shield the positive charge of
the formed particles, a monodisperse PEG24 was in-
corporated into the carrier structure at a defined
position. The efficient shielding blocks siRNA nanopar-
ticle aggregation and led to nanoparticles with a
hydrodynamic diameter of 5.8 nm, only 1.4-fold larger
than free siRNA with 4.2 nm hydrodynamic diameter
(Table 1). The particle size does not increase with
higher N/P ratios beyond 6, further supporting the
notion that polyplex formation is a saturable process.
This was further confirmed by fluorescence correlation
spectroscopy measurements of Alexa488-labeled oli-
gomer and siRNA-Inf7 polyplexes (Table S1). Free
oligomer had a hydrodynamic diameter of 2.3 nm. A
two-component fit of polyplexes formed at N/P 6
resulted in two labeled populations, one with a hydro-
dynamic radius of ∼2 nm (free oligomer, 63%) and a
second with a hydrodynamic diameter of ∼7.4 nm
(polyplexes, 37%). Thus, one-third of the polycation is
bound in polyplexes (actual N/P ≈ 2) and two-thirds
remain free in solution. This is well consistent with the
literature.31 Upon increasing the PEG spacer to a 3-fold
length (oligomer 483, FolA-PEG72-K(Stp4-C)2; see
Figure S14, Table S3), the nanoparticle size increases
to 8.8 nm hydrodynamic diameter. This is consistent
with the 3-fold PEG polymer length (diameter increases
about 1.5 nm per PEG24 unit).
The PEGylated siRNA nanoparticles have an overall
zeta potential of 0 mV ((3 mV) (see Table S2). Particles
formed with the same oligomer lacking the polyethy-
lene glycol structure (202) formmuch larger, 60900 nm,
nanoparticles and aggregates (see Table S4) and show
Figure 3. Functionality and necessity of carrier substructures. (a) Stabilization via disulfide cross-linking by gel shift assay at
indicatedN/P ratios. C: free siRNA-Inf7 control. (b) Shielding and targeting. KB cells were transfected usingCy5-labeled siRNA-
Inf7 in combination with targeted, PEGylated oligomer 356 containing cysteines (black), untargeted PEGylated oligomer 188
containing cysteines (blue), or targeted PEGylated oligomer 420 lacking cysteines (red). After 30 min cells were washed,
analyzed by FACS, and compared to nontransfected cells (green). (c) Functionality of modified Inf7 peptide. Lysis activity of
5 μMsiRNA-Inf7 (blue bars) was compared to the lysis activity of 5 μM free Inf7 peptide (purple bars) in an erythrocyte leakage
assay. (d) Functionality of modified siRNA. Neuro2A/eGFPLuc cells transfected with 400 nM siRNA-Inf7 (blue bars) or 400 nM
unmodified siRNA (purple bars) using the functional, polycationic carrier 46 at indicated N/P ratios. Luciferase activity was
determined after 48 h without medium exchange. Reporter gene knockdown is shown as percentage of untreated cells.
TABLE 1. Hydrodynamic Diameter (dh) of Polyplexes
Formed Using Cy5-Labeled siRNA-Inf7 in Combination
with FolA-PEG24-K(Stp4-C)2 Determined by Fluorescence
Correlation Spectroscopya
N/P dh [nm] D [m
2/s]
0 (siRNA) 4.2 ( 0.2) 10.0  1011 ( 3  1012)
3 5.4 ( 0.2) 8.2  1011 ( 2  1012)
6 5.8 ( 0.2) 7.7  1011 ( 2  1012)
12 6.0 ( 0.2) 7.7  1011 ( 2  1012)
16 6.0 ( 0.2) 7.7  1011 ( 2  1012)
20 5.6 ( 0.2) 7.9  1011 ( 2  1012)
40 5.6 ( 0.2) 8.1  1011 ( 2  1012)
a D: diffusion coefficient. A single Cy5 label conjugated with the siRNA would not be
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a significantly higher zeta potential, between 10 and
15mV (Table S2). Uncharged particles cannot attach to
the cell surface via electrostatic interactions. Thus they
would not interact randomly with cell surfaces and
blood proteins32,33 when injected intravenously; how-
ever, they are not able to actively enter their target cells
either. To enable an efficient receptor-mediated cellu-
lar uptake of the polyplex, folic acid was covalently
attached to the PEG shield. As this ligand has a very
high binding affinity to its receptor,34,35 it should
selectively mediate cell attachment and endocytosis
into its target cell. To demonstrate this, polyplexes
were formed with siRNA-Inf7 bearing a fluorescent
Cy5 label. After transfection of KB cells, expressing
the folic acid receptor or Neuro2A cells as negative
control, cellular uptake was analyzed quantitatively by
flow cytometry measurement (Figures 3b and S8). The
results reveal that the particle shielding is very efficient.
No fluorescent signal was detected in cells when
carriers lacking the targeting ligand were employed.
When transfected with folate-targeted particles, cells
show a significantly increased uptake by flow cyto-
metric analysis when receptor-positive KB cells were
used. In the case of Neuro2A cells, with a low folic acid
receptor level, very moderate uptake could be ob-
served. Competitionwith an excess of free folic acid leads
to a strongly reduced cellular association (Figure S8).
These results could be confirmed by microscopic
analysis (Figure S9).
The second component of the delivery system is the
endosomolytic-active siRNA-Inf7 conjugate. To de-
monstrate its functionality, the lytic activity was tested
in comparison to free, unconjugated Inf7 peptide using
an erythrocyte leakage assay. As shown in Figure 3c the
free peptide has no lytic activity at physiological pH
(pH of the extracellular environment and the cytosol),
while the lytic activity is significantly increased at pH
5.5, mimicking the endosomal environment (as pre-
viously reported18). The lytic activity of the siRNA-
conjugated peptide shows no significant differences
compared to the free peptide, revealing that it remains
fully functional upon conjugation to the C-terminus.
The preserved silencing activity of the conjugated
siRNA was first shown in comparison to unmodified
siRNA in a standard setting, transfecting Neuro2A/
eGFPLuc cells (Figure 3d and Figure S10) using the
defined but untargeted polycationic carrier 46.27 Re-
sults reveal that the silencing efficiency as well as
cytotoxicity is not negatively affectedby the attachment
of the endosomolytic peptide via a disulfide linkage.
Efficient and Specific Reporter Gene Silencing in Vitro.
Although all single substructures were shown to work
as expected, the delivery system in total had to prove
its transfection potency and gene silencing efficiency
together with specificity to the target cell population
and the absence of cytotoxicity. For this purpose KB
cells (expressing the folate receptor) stably expressing
an eGFP-luciferase fusion protein were used as repor-
ter system. To demonstrate the importance of every
single component of the system, controls lacking
the folic acid ligand (188), the cysteine cross-linking
ability (420), or the endosomolytic peptide were used.
A nontargeting siRNA (siCtrl) was transfected to de-
monstrate specificity of target silencing. The results
(Figure 4a, right lanes) clearly show that all controls lack
silencing efficiency under the transfection conditions
employed. The only control showing a significant but
weak knockdown is the combination of unconjugated
siRNA and functional carrier (356) at high N/P ratios.
We conclude that the protone sponge effect of the
polyamino backbone exists, but in the context of the
very small PEGylated polyplexes on its own is not
Figure 4. In vitro gene silencing using FolA-PEG24-K(Stp4-C)2 (356) and siRNA-Inf7. (a) Luciferase reporter gene knockdown.
KB/eGFPLuc cells were transfected using the functional carrier (356) in combination with siGFP-Inf7 (purple bars) or with
unmodified siGFP (black bars) at indicated N/P ratios. Control transfections were performed using carriers lacking either the
targeting ligand (188, dark blue bars) or the cross-linking ability (420, light blue bars). To show specificity of knockdown, cells
were transfected using the functional oligomer in combinationwith siCtrl-Inf7 (white bars). (b) Microscopic pictures of in vitro
knockdown experiments using EG5 as endogenic target. KB cells were transfected using siEG5-Inf7 in combinationwith FolA-
PEG24-K(Stp4-C)2 (356, I) or A-PEG24-K(Stp4-C)2 (188, III), or siCtrl-Inf7 in combination with FolA-PEG24-K(Stp4-C)2 (356, II) or
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strong enough for endosomal escape. In contrast, a
clear and significant silencing of the target gene
(Figure 4a, left lanes) was obtained by combination
of the functional carrier systemwith the endosomolytic
siRNA-Inf7 conjugate, demonstrating the efficiency
of the delivery system. An in vitro doseresponse
curve (Figure S11) comparing targeted (356) and non-
targeted (188) polyplexes demonstrated a ligand-,
Inf7-, and eGFP-sequence-dependent gene silencing
at siRNA doses as low as <6 nM. A direct comparison
with the commercially available transfection agent
Lipofectamine under recommended conditions (serum-
free, 4 h incubation) revealed for carrier 356 at short
incubation (only 30 min, standard cell culture con-
ditions) a high gene silencing efficiency at reduced
toxicity (Figure S12). The replacement of the bio-
degradable disulfide linkage between siRNA and Inf7
by a noncleavable thioether bond resulted in a far
lower silencing activity (Figure S13). To further char-
acterize the gene silencing activity, an endogenous
target was selected. The gene EG5 (also known as KSP)
plays a crucial role during the cell cycle. The silencing of
thisgenehasbeenshownto result inmitotic cell arrest and
characteristic mitotic figure formation (“mitotic aster”).36
Thus KB cells were transfected with siEG5-Inf7, com-
plexedwith functional carrier or control oligomers. After
staining, the microscopic pictures show the character-
istic aster formation of themitotic chromatin, indicating
the specific knockdown of the target gene (Figure 4b, I).
None of the control formulations led to this aster
formation (Figure 4b, IIIV).
Tumor Target Gene Silencing in Vivo. The designed sys-
tem has shown to work as expected in vitro. Thus the
carrier was tested further in an in vivo setting. For this
purpose polyplexes were prepared at N/P 16, based
on the best in vitro transfection results due to the
synergistic effect of endosomal buffering and swelling
agent (oligoethanamino core) and endosomolytic in-
fluenza peptide. In the first experiments, polyplexes
were injected intratumoraly, into subcutaneous tu-
mors of NMRI nude mice, to determine whether the
carrier is functional after reaching the tumor tissue.
Near infrared (NIR) fluorescence imaging experiments
using Cy7-labeled siRNA (Figures 5a and S18) proved
that the incorporation of folic acid as targeting ligand
results in a significantly increased retention in the
tumor tissue compared to nontargeted particles. When
injecting free siRNA, almost no retention and a fast
clearance can be observed. Although a clear tumor-
targeting effect could be shown within this imaging
experiment, the intracellular delivery of the siRNA and
thus the functionality of the carrier had to be evaluated
in a target gene silencing experiment. For this purpose
EG5-Inf7 siRNA was injected intratumoraly, using FolA-
PEG24-K(Stp4-C)2 (356) as carrier. In stained tumor
slices of tumors harvested 24 h after treatment the
formation of asters could be detected (Figure 5b). In
contrast, no mitotic figures were observed in the case
of siCtrl-Inf7-treated tumors.
As the intratumoral delivery was shown to work
efficiently, proving folic acid targeting and gene silen-
cing, the behavior of these nanosized particles after
systemic application was evaluated. Interestingly, NIR
fluorescence imaging revealed a short circulation time
of 15 min followed by fast clearance through renal
filtration, which can be explained by the small particle
size (Figure 6a). Renal clearance was not influenced by
the presence/absence of the folate targeting ligand
(data not shown). Importantly, due to the excellent
shielding of the polyplexes, unspecific affinity to tis-
sues such as lung, liver, or spleen often observed with
nanoparticles was not detectable (Figure 6b). Carriers
Figure 5. Intratumoral injectionof siRNApolyplexes. (a) Retentionof targetedpolyplexes at the tumor site determinedbyNIR
fluorescence bioimaging. FolA-targeted polyplexes (356, top), untargeted polyplexes (188, center), and equal amounts (25 μg)
of free Cy7-labeled siRNA (bottom). (b) Mitotic figure formation 24 h after intratumoral injection of targeted polyplexes in
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with longer precise PEG spacers, FolA-PEG48-K(Stp4-C)2
(482) and FolA-PEG72-K(Stp4-C)2 (483), increase the
size of formed siRNA nanoparticles from 5.8 nm (356)
up to 8.8 nm (483) hydrodynamic diameter (Figure S14
and Table S3). These polyplexes have very comparable
in vitro gene silencing efficiency (Figure S15) and also
in vivo distribution kinetics (Figure S16). In vivo stability
of nanoparticles could be demonstrated detecting
siRNA-loaded polyplexes but no free siRNA in the urine
of intravenously treated mice (Figure S17). Although
no significant amounts of labeled siRNA were found in
the tumor tissue, still some aster formation was ob-
served using siEG5-Inf7 but not control siCtrl-Inf7
polyplexes (Figure 6c), demonstrating a moderate
gene silencing effect. Efficacy was clearly lower than
in the case of intratumoral administration, with
3-fold lower frequency of aster formations (by histo-
logical count) after i.v. injection as compared to i.t.
injection. The moderate performance upon systemic
application is not surprising considering the rapid
renal clearance.
CONCLUSION
We developed a highly functionalized and on mol-
ecular level defined carrier system for siRNA delivery in
vitro and in vivo. The design of a chemically precise
cationic (oligoethanamino)amide backbone carrying
PEG for surface shielding attached to folic acid as
targeting ligand and cysteines for bioreversible inter-
nal polyplex stabilization, combined with an endoso-
molytic influenza peptidesiRNA conjugate, results in
a specific and efficient delivery system. The synthetic
concept based on solid phase supported peptide
chemistry allows full control over the structural design
of the cationic carrier, overcoming many problems faced
by macromolecular carrier synthesis. The monodisperse
structures were thoroughly analyzed, and very stable
siRNA polyplex formation could be established. The
requirement of every single substructure could be de-
monstrated in individual experiments by com-
parison with the same system lacking the according
substructure. The requirement of each individual
function could be demonstrated by silencing a re-
porter gene or an endogenous target, EG5/KSP, in
tumors both in vitro and in vivo. In addition, receptor
target specificity could be demonstrated by near-
infrared fluorescence imaging experiments. The
nanosized appearance of these functionally active
particles (controlled by polymer design; in the cur-
rent study from 5.8 up to 8.8 nm hydrodynamic
diameter) in combination with the high stability
and complete surface charge shielding resulted in
high tolerability in vivo and the absence of unspecific
accumulation in nontargeted tissue such as liver,
lung, or spleen.
The presented study demonstrates that functionally
sophisticated but still molecularly monodisperse deliv-
ery systems can be generated by convenient solid
phase syntheses, which allow the determination of
clear structureactivity relationships and simplifies
reproducible and scalable manufacturing. Based on
the current proof of concept study for this kind of
delivery system, the overall strategy enables the gen-
eration of a variety of nucleic acid carriers with other
targeting ligands (including peptides, our unpublished
results), altered degree and type of shielding, different
Figure 6. Intravenous administration of siRNA polyplexes. (a) Time-dependent distribution of 50 μg Cy7-labeled siRNA after
intravenous injection using FolA-PEG24-K(Stp4-C)2 (356) as carrier. Upper panel: ventral position. Lower panel: dorsal position.
(b) Organs at 1 h after injection. (c) Histochemical analysis of gene silencing (three tumor sections) by detection of aster
formation.Mice were treated intravenously with FolA-PEG24-K(Stp4-C)2 (356) or A-PEG24-K(Stp4-C)2 (188) in combinationwith
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polymeric backbone, or endosomal escape domains,
leading always to a defined, monodisperse struc-
ture with specific properties. Therefore, the devised
strategy widens the scope of vector design for the
development of efficient siRNA, pDNA, and other
oligonucleotide carrier systems.
METHODS
Synthesis of Folic Acid Targeted Polycations and Its Controls. Oligo-
mers (sequences are listed in Table S5) were synthesized by
standard Fmoc-based solid phase supported peptide synthesis
using novel building blocks.28 As solid support 2-chlorotrityl
chloride resin was used.
To load the first amino acid, the resin was swollen in
dichloromethane (DCM) for 30 min and N,N-dimethylforma-
mide (DMF) for 10 min. Then 0.5 equiv of Fmoc-Cys(Trt)-OH and
10 equiv of diisopropylethylamine (DIPEA) were added in dry
DCM. After 60 min incubation methanol (0.8 mL/g resin) was
added. Themixture was incubated for an additional 30min. The
resin was washed five times with DMF and five times with DCM.
To quantify the loading, the resin was dried in vacuo. After
cleaving the Fmoc protecting group it was quantified by
absorption measurement at 301 nm. For carrier chain elonga-
tion building blocks (4 equiv) were activated with PyBOP/HOBt
(4 equiv) and DIPEA (8 equiv) in DCM/DMF, 1:1 (v/v), and the
resinwas incubated until the Kaiser test indicated completion of
reaction. Removal of the Fmoc protecting groups was per-
formed by washing the resin four times for 10 min with 20%
piperidine in DMF.
The functional construct (FolA-PEG24-K(Stp4-C)2) was syn-
thesized starting with a resin-bound Cys(Trt). First the poly-
amido backbone was generated by sequential coupling of 4
Stp building blocks, a Dde-Lys(Fmoc)-OH as branching unit, 4
additional Stp building blocks, and finally Boc-Cys(Trt)-OH. The
Dde protecting group was removed by washing the resin with
2% hydrazine in DMF until completion of cleavage was con-
firmed by lack of absorption at 290 nm. At the free amine the
synthesis was continued, adding first a defined Fmoc-PEG24-OH
(QuantaBiodesign, Powell, OH, USA) building block followed by
Fmoc-Glu-OtBu and finally N10-(trifluoroacetyl)pteroic acid. The
tfa-protecting group was removed using 1 M ammonium
hydroxide/DMF, 1:1 (v/v). The resin was dried in vacuo. As
cleavage cocktail TFA/TIS/water (95:2.5:2.5) at an incubation
time of 1 h was used. After evaporation of solvents, the peptide
was precipitated twice in ice cold methyl tertiary butyl ether
(MTBE)/n-hexane, 1:1 (v/v), dissolved in 0.1% TFA in water, and
lyophilized.
The serine control (FolA-PEG24-K(Stp4-S)2) was synthesized
according to the described procedure using resin bound Ser-
(tBu) and adding a Fmoc-Ser(tBu)-OH at the end of the se-
quence followed by bocylation of the N-terminus.
The untargeted control was synthesized persuing the same
conditions, starting with resin-bound Fmoc-Ala-OH and Fmoc-
Lys(Fmoc)-OH as branching unit.
The identity of the structure was confirmed by MALDI-MS,
and the purity was established by analytical RP-HPLC.
Synthesis of Endosomolytic-Active siRNAPeptide Conjugate. The
used siRNA was modified at its 50-end with a C6-ss-C6 spacer.
The siRNA was incubated with tris(2-chlorethyl)phosphate
(10 equiv) for 30 min at 25 C, resulting in siRNA with a free
thiol group. Purification was performed on a 1 mL ResourceQ-
column connected to an Äkta basic system. The sample was
loaded onto the column using a 20 mM HEPES buffer (pH 6.5)
containing 50 mM sodium chloride. After washing the column
with the same buffer containing 200 mM sodium chloride the
product was eluted running a sodium chloride gradient of
10 mM/min at a flow of 1 mL/min. Fractions containing siRNA
were pooled. For activation of the thiol, the siRNA was incu-
bated with 5,50-dithiobis(2-nitrobenzoic acid) (10 equiv) for 1 h
at RT. The resulting product was purified employing the same
conditions as described above. The resulting activated siRNA
was incubated with 1.5 equiv of Inf7peptide (GLFE AIEG FIEN
GWEG MIDG WYGC, Biosyntan, Berlin, Germany). The result-
ing siRNApeptide conjugate was purified using the same
conditions as described above. Fractions of 0.5 mL were col-
lected and analyzed in a 2.5% agarose gel (100 V for 100 min).
Fractions containing gel-retarded siRNA compared to a uncon-
jugated input siRNA were pooled. Identity was checked by
MALDI-TOF-MS analysis.
MALDI-TOF-MS Analyses. Peptidic Carrier Molecules. Analysis of
peptidic carrier molecules was performed at Roche Kulmbach.
Samples were dissolved in H2O containing 0.1% TFA and
adjusted to a final concentration of approximately 0.1 mg/mL.
For MALDI-TOF-MS stainless steel targets were used. Samples
(1 μL) were spotted onto a 1 μL matrix droplet consisting of a
2,5-dihydroxybenzoic acid solution (10 mg/mL) in 50% acetoni-
trile with 0.1% TFA. Samples were air-dried and analyzed
employing an Autoflex II mass spectrometer (Bruker Daltonics,
Bremen, Germany) in reflectormode. Desorption of the samples
was achieved by a nitrogen laser (337 nm), and probes were
accelerated with 19 kV. For one sample spectrum, 100200
individual spectra of the respective probes were averaged. A
peptide standard served as an external calibration mixture.
Nucleic Acid Constructs. Samples were used as collected
after ion exchange purification. To minimize additional salt
peaks, 5 μL of the samples was desalted by drop dialysis using
an ultrafiltration membrane (Millipore) on a Petri dish filled with
H2O for 2 h. Then 0.5 μL of this solution was spotted on a 0.5 μL
matrix droplet consisting of a saturated solution of 3-hydro-
xypicolinic acid in 50% acetonitrile. Samples were analyzed
using an Autoflex II mass spectrometer (Bruker Daltonics). For
one sample spectrum, 50100 spectra of respective probes
were averaged.
Analytical RP-HPLC. Determination of sample purity was per-
formed using a Waters HPLC system consisting of a P-900
gradient pump system and a 996 photodiode array detector.
All peptidic structures were analyzed using a Sunfire C18 column
(5 μm, 4.6  150 mm), using a water/acetonitrile gradient (95:5
to 0:100 in 20min) containing 0.1% TFA. Analysis was performed
using a detection wavelength of 214 nm.
Erythrocyte Leakage Assay. Murine erythrocytes were isolated
from fresh, citrate-buffered blood and washed with phosphate-
buffered saline (PBS) until the supernatant remained clear. The
erythrocytes were diluted in PBS (pH 5.5, 6.5, or 7.4) to 107
erythrocytes/mL. The siRNApeptide hybrid or free peptide
was diluted in 75 μL of PBS (pH 5.5, 6.5, or 7.4) to a concentration
of 10 μM. Using a V-bottom 96-well plate (NUNC, Denmark),
75 μL of erythrocyte suspension was mixed with 75 μL of
peptide solution. For 100% lysis, cells were mixed with 75 μL
of 1% Triton X-100. After incubation for 1 h at 37 C under
constant shaking the erythrocytes were centrifuged. A 80 μL
portion of the supernatant was analyzed for hemoglobin re-
lease at 405 nm using a microplate plate reader (Spectrafluor
Plus, Tecan Austria GmbH, Grödig, Austria). Measurement data
are presented as mean of triplicates.
Cell Culture. Human cervix carcinoma cells were used either
as wild-type (KB cells) or stably transfected with the eGFP-
luciferase gene (KB/eGFPLuc cells). Cells were grown in folate-
free RPMI 1640 medium (Invitrogen, Germany), supplemented
with 10% fetal calf serum (FCS), 4mMstable glutamine, 100U/mL
penicillin, and 100 μg/mL streptomycin.
As a control murine neuroblastoma cells either wild-type
(Neuro2A) or stably transfected with the eGFP-luciferase gene
(Neuro2A/eGFPLuc) were grown in Dulbecco's modified Eagle's
medium, supplemented with 10% FCS, 4 mM stable glutamine,
100 U/mL penicillin, and 100 μg/mL streptomycin.
Polyplex Formation. A 270 ng amount of siRNA and the
calculated amount of polycation at different N/P ratios (proton-
atable nitrogens of polycation/phosphate groups of nucleic
acid) were diluted in separate Eppendorf tubes each containing
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followed by addition of polycation solution to the siRNA solu-
tion and rapid mixing by pipetting up and down (minimum five
times) and incubation for 45120 min at RT under air, in order
to allow formation of polyplexeswith internal disulfide links due
to air oxidation of the oligomer thiols during the polyplex
formation time.27,29 Disulfide formation was quantified with
Ellman's assay as described therein.27,29 Reduction of free thiol
groups was used as an indicator of disulfide formation. See for
example Figure S19 in the Supporting Information.
In Vitro Reporter Gene Silencing. In vitro gene silencing experi-
ments were performed with stably transfected KB/eGFPLuc or
Neuro2A/eGFPLuc cells. Used siRNAs were either the unmodi-
fied siRNAs siGFP (sense: 50-AuAucAuGGccGAcAAGcAdTsdT-30 ;
antisense: 50-UGCUUGUCGGCcAUGAuAUdTsdT-30) for silencing
the eGFPLuc fusion protein and its control sequence siCtrl
(sense: 50-AuGuAuuGGccuGuAuuAGdTsdT-30 ; antisense: 50-
CuAAuAcAGGCcAAuAcAUdTsdT-30) or the peptide modified
sequences siGFP-Inf7 (sense: Inf7-ss-C6-50-AuAucAuGGccGA-
cAAGcAdTsdT-30 ; antisense: 50-UGCUUGUCGGCcAUGAuAUdTsdT-30)
and its control sequence siCtrl-Inf7 (sense: Inf7-ss-C6-50-Au-
GuAuuGGccuGuAuuAGdTsdT-30 ; antisense: 50-CuAAuAcAGGC-
cAAuAcAUdTsdT-30) (small letters: 20-methoxy-RNA; s: phos-
phorothioate). Silencing experiments were performed in 96-
well plates with 5000 cells per well in triplicates with a final
siRNA concentration of 200 nM unless otherwise stated. Cells
were seeded 24 h prior to transfection. On the day of transfec-
tion, medium was replaced by 80 μL of fresh folate-free RPMI
1640 medium containing 10% FCS. Polyplexes were formed for
45min at different N/P ratios in 20 μL of HBG added to each well
and incubated at 37 C for 48 h. For targeting experiments
polyplexes were removed bymedium exchange after 30min. In
competition experiments, cells were incubated with free folic
acid on ice 30 min prior to the transfection experiment. At 48 h
post-transfection medium was removed. The cells were treated
with 100 μL of cell lysis buffer (25 mM Tris, pH 7.8, 2 mM EDTA,
2 mM DTT, 10% glycerol, 1% Triton X-100). Luciferase activity in
the lysate (35 μL) was measured using a luciferase assay kit
(100 μL luciferase assay buffer, Promega, Mannheim, Germany)
on a luminometer for 10 s (Lumat LB9507 instrument, Berthold,
Bad Wildbad, Germany). The relative light units were related to
buffer-treated control cells.
FluorescenceMicroscopy of Aster Formation in Vitro. KB cells (1 104)
were seeded in 200 μL of folate-free RPMI medium supple-
mented with 10% FCS using eight-well Labtek chamberslides.
Twenty-four hours after seedingmediumwas replaced by 180 μL
of fresh medium, siRNA polyplexes were added (50 μL formed
in HBG). Experiments were performed using 1 μg/well EG5-
siRNA (sense: 50-ucGAGAAucuAAAcuAAcudTsdT-30 ; antisense:
50-AGUuAGUUuAGAUUCUCGAdTsdT-30 , 1 μg/well siCtrl or buffer
(HBG). Medium was replaced by fresh medium 30 min after
transfection. After 24 h transfection medium was removed and
cells were washed with 200 μL of PBS and fixed with paraform-
aldehyde (4%). Nuclei were stained with DAPI, and results were
documented using a Zeiss Axiovert 200 (fluorescence micro-
scope, Carl Zeiss AG, Germany) and a Zeiss LSM510 Meta laser
scanning microscope.
Flow Cytometric Measurement of Polyplex Uptake. Cells were
seeded into 24-well plates at a density of 5  104 cells/well.
After 24 h, culture medium was replaced with 400 μL of fresh
growth medium containing 10% FCS. Transfection complexes
for siRNA delivery (Cy5-labeled siRNA-Inf7) at an N/P ratio of
16 (100 μL in HBG) were added to each well and incubated at
37 C for 30 min (final siRNA concentration: 200 nM). All experi-
ments were performed in duplicates. Subsequently, cells were
washed twice with PBS. Cells were detached with trypsin/EDTA
and taken up in PBS with 10% FCS, and flow cytometry was
performed using a Cyan ADP flow cytometer (Dako, Ham-
burg, Germany). Cellular uptake was assayed by excitation of
Cy5 at 635 nm and detection of emission at 665 nm. To
discriminate between viable and dead cells, cells were appro-
priately gated by forward/sideward scatter and pulse width
and counterstained with DAPI, and 1  104 gated events per
sample were collected. Data were recorded by Summit soft-
ware (Summit, Jamesville, NY, USA) and evaluated by FlowJo
software.
Measurement of Particle Size via Fluorescence Correlation Spectroscopy.
The particle size of polyplexes was measured by fluorescence
correlation spectroscopy using an Axiovert 200 microscope
with a ConfoCor2 unit (Carl Zeiss, Jena, Germany). A HeNe laser
(633 nm, average power of 50 μW at the sample) was used for
excitation. The objective was a 40 (NA = 1.2) water immersion
apochromat (Carl Zeiss, Jena, Germany). Particles were formed
in a volumeof 10μL of HBGwith a final concentration of 14.8 μM
siRNA-Inf7, including 50 nM Cy5-labeled siRNA-Inf7 at indicated
N/P ratios. For size measurements using labeled cation, oligo-
mer 583 was used during polyplex formation. After polyplex
formation the particles were filled up with 200 μL of HBG and
transferred to eight-well LabTek I chamber slides (NUNC, Wies-
baden, Germany) for measurement. Three experimental repli-
cates were measured.
Measurement of Zeta Potential. Polyplexes, containing 10 μg
siRNA, were prepared in 370 μL of HBG and filled up with HEPES
(20mM, pH 7.4) to 1mLbeforemeasurement. The sampleswere
measured in triplicate using a Zetasizer Nano ZS (Malvern
Instruments, Worcestershire, U.K.)
siRNA Binding Assay. A 2.5% agarose gel containing GelRed
was prepared. Polyplexes containing 500 ng of siRNA and
cationic oligoaminoamide carriers in different N/P ratios were
prepared and mixed with loading buffer (6 mL of glycerine,
1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g of xylene cyanol).
Electrophoresis was performed at 80 V for 40 min.
In Vivo Experiments. Female Rj:NMRI-nu (nu/nu) (Janvier, Le
Genest-St-Isle, France) mice were housed in isolated ventilated
cages under specific pathogen-free conditions with a 12 h day/
night cycle and food and water ad libitum. Human cervix
carcinoma cells (KB wild-type) were cultured as described
above. About 5  106 cells were injected subcutaneously into
the nape of nude mice at an age of 6 weeks. Polyplexes con-
taining 50 μg of siRNA (N/P 16) or pure siRNA solved in 50 μL
(intratumoral injection) or 250 μL (intravenous injection) of HBG
were injected either into the tumor or into the tail vein of tumor-
bearing mice. All animal experiments were performed accord-
ing to the guidelines of the German law for protection of animal
life and approved by the local ethics committee.
In Vivo Near-Infrared Fluorescence Imaging. Near-infrared fluores-
cence imaging was performed using the IVIS Lumina system
with Living Image software 3.2 (Caliper Life Sciences, Hopkin-
ton, MA, USA). Mice were anesthetized with 3% isoflurane in
oxygen. For the distribution analysis of the polyplexes FolA-
PEG24-K(Stp4-C)2, FolA-PEG48-K(Stp4-C)2, or FolA-PEG72-K(Stp4-C)2
each containing Cy7-labeled siAHA1 (sense: 50-(Cy7)(NHC6)-
GGAuGAAGuGGAGAuuAGudTsdT-30 ; antisense: 50-ACuAAUCU-
CcACUUcAUCCdTsdT-30) were injected intravenously. Fluores-
cence measurement by a CCD camera was started immedi-
ately after injection and repeated after 0.25, 1, 4, and 24 h. To
demonstrate the functionality of receptor targeting in vivo FolA-
PEG24-K(Stp4-C)2 containing siAHA1-Cy7, A-PEG24-K(Stp4-C)2
containing siAHA1-Cy7, or pure siAHA1-Cy7 was injected in-
tratumorally. Fluorescence signal was measured after 0, 4, 24,
48, 72, 96, and 120 h. Data interpretation was done with
equalized color bar scales for each trial.
Urine Sample Collection. For the analysis of the polyplex stabi-
lity by gel electrophoresis urine was collected by bladder
puncture. Mice treated intravenously with FolA-PEG24-K(Stp4-
C)2 containing Cy7-labeled siAHA1, FolA-PEG72-K(Stp4-C)2 con-
taining Cy7-labeled siAHA1, or pure siEG5-Inf7 were anesthe-
tized 4 h after application and blindly punctured in the dorsal
position with an insulin syringe.
EG5 Knockdown As Evaluation of Gene Silencing in Vivo. In the
intratumoral EG5 knockdown experiment, mice were injected
with FolA-PEG24-K(Stp4-C)2 combined with siEG5-Inf7 or siCtrl-
Inf7 intratumorally also 48 and 24 h before euthanasia. Tumors
were harvested, fixed in formalin, and embedded into paraffin.
Then the tumors were cut into 4.5 μm slices. After hematoxylin
and eosin staining, results were documented using an Olympus
BX41 microscope (Olympus, Germany). In the intravenous
EG5 knockdown experiments, mice were treated intravenously
with FolA-PEG24-K(Stp4-C)2 containing siEG5-Inf7, FolA-PEG24-
K(Stp4-C)2 containing siCtrl-Inf7, or A-PEG24-K(Stp4-C)2 contain-
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harvested and embedded into Tissue-Tek. Then tumors were
cut into 5 μm slices using a cryotom, fixed with paraformalde-
hyde, and stained with DAPI. Results were documented with a
Zeiss Axiovert 200 fluorescence microscope (Carl Zeiss AG,
Germany).
Conflict of Interest: The authors declare no competing
financial interest.
Acknowledgment. This work was supported by the DFG
Cluster “Nanosystems Initiative Munich”, a grant from Roche
Kulmbach, and the Biotech Cluster m4 T12.
Supporting Information Available: Data on structural anal-
ysis, size, and zeta potential, FACS data andmicroscopic pictures
of uptake, toxicity in vitro, distribution in vivo, structure and
functionality of structures with longer PEG chains, urine anal-
ysis, and aster detection after systemic administration. This
material is available free of charge via the Internet at http://
pubs.acs.org.
REFERENCES AND NOTES
1. Gao, K.; Huang, L. Nonviral Methods for SiRNA Delivery.
Mol. Pharm. 2009, 6, 651–658.
2. Wang, J.; Lu, Z.; Wientjes, M. G.; Au, J. L. Delivery of SiRNA
Therapeutics: Barriers and Carriers. AAPS J. 2010, 12, 492–
503.
3. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Factors
Affecting the Clearance and Biodistribution of Polymeric
Nanoparticles. Mol. Pharm. 2008, 5, 505–515.
4. Kwok, A.; Hart, S. L. Comparative Structural and Functional
Studies of Nanoparticle Formulations for DNA and SiRNA
Delivery. Nanomedicine 2011, 7, 210–219.
5. Meade, B. R.; Dowdy, S. F. The Road to Therapeutic RNA
Interference (RNAi): Tackling the 800 Pound Sirna Delivery
Gorilla. Discovery Med. 2009, 8, 253–256.
6. Xing, J.; Deng, L.; Guo, S.; Dong, A.; Liang, X. J. Polycationic
Nanoparticles as Nonviral Vectors Employed for Gene
Therapy in Vivo. Mini-Rev. Med. Chem. 2010, 10, 126–137.
7. Wagner, E. Polymers for SiRNA Delivery: Inspired by
Viruses to Be Targeted, Dynamic, and Precise. Acc. Chem.
Res. 2012, http://dx.doi.org/10.1021/ar2002232.
8. Andaloussi, S. E.; Lehto, T.; Mager, I.; Rosenthal-Aizman, K.;
Oprea, I. I.; Simonson, O. E.; Sork, H.; Ezzat, K.; Copolovici,
D. M.; Kurrikoff, K.; et al. Design of a Peptide-Based Vector,
Pepfect6, for Efficient Delivery of SiRNA in Cell Culture and
Systemically in Vivo. Nucleic Acids Res. 2011, 39, 3972–
3987.
9. Matsumoto, S.; Christie, R. J.; Nishiyama, N.; Miyata, K.; Ishii,
A.; Oba, M.; Koyama, H.; Yamasaki, Y.; Kataoka, K. Environ-
ment-Responsive Block Copolymer Micelles with a Disul-
fide Cross-Linked Core for Enhanced SiRNA Delivery.
Biomacromolecules 2009, 10, 119–127.
10. Rozema, D. B.; Lewis, D. L.; Wakefield, D. H.; Wong, S. C.;
Klein, J. J.; Roesch, P. L.; Bertin, S. L.; Reppen, T. W.; Chu, Q.;
Blokhin, A. V.; et al. Dynamic Polyconjugates for Targeted
in Vivo Delivery of SiRNA to Hepatocytes. Proc. Natl. Acad.
Sci. U. S. A. 2007, 104, 12982–12987.
11. Creusat, G.; Thomann, J. S.; Maglott, A.; Pons, B.; Donten-
will, M.; Guerin, E.; Frisch, B.; Zuber, G. Pyridylthiourea-
Grafted Polyethylenimine Offers an Effective Assistance to
SiRNA-Mediated Gene Silencing in Vitro and in Vivo.
J. Controlled Release 2012, 157, 418–426.
12. Mao, S.; Neu, M.; Germershaus, O.; Merkel, O.; Sitterberg, J.;
Bakowsky, U.; Kissel, T. Influence of Polyethylene Glycol
Chain Length on the Physicochemical and Biological
Properties of Poly(Ethylene Imine)-Graft-Poly(Ethylene
Glycol) Block Copolymer/SiRNA Polyplexes. Bioconjugate
Chem. 2006, 17, 1209–1218.
13. Malek, A.; Czubayko, F.; Aigner, A. Peg Grafting of Poly-
ethylenimine (PEI) Exerts Different Effects on DNA Trans-
fection and SiRNA-Induced Gene Targeting Efficacy.
J. Drug Targeting 2008, 16, 124–139.
14. Taratula, O.; Garbuzenko, O. B.; Kirkpatrick, P.; Pandya, I.;
Savla, R.; Pozharov, V. P.; He, H.; Minko, T. Surface-Engineered
Targeted PPI Dendrimer for Efficient Intracellular and Intra-
tumoral SiRNADelivery. J. Controlled Release 2009, 140, 284–
293.
15. Walker, G. F.; Fella, C.; Pelisek, J.; Fahrmeir, J.; Boeckle, S.;
Ogris, M.; Wagner, E. Toward Synthetic Viruses: Endosomal
pH-Triggered Deshielding of Targeted Polyplexes Greatly
Enhances Gene Transfer in Vitro and in Vivo. Mol. Ther.
2005, 11, 418–425.
16. Meyer, M.; Philipp, A.; Oskuee, R.; Schmidt, C.; Wagner, E.
Breathing Life into Polycations: Functionalization with pH-
Responsive Endosomolytic Peptides and Polyethylene
Glycol Enables SiRNA Delivery. J. Am. Chem. Soc. 2008,
130, 3272–3273.
17. Ikeda, Y.; Taira, K. Ligand-Targeted Delivery of Therapeutic
SiRNA. Pharm. Res. 2006, 23, 1631–1640.
18. Plank, C.; Oberhauser, B.; Mechtler, K.; Koch, C.; Wagner, E.
The Influence of Endosome-Disruptive Peptides on Gene
Transfer Using Synthetic Virus-Like Gene Transfer Systems.
J. Biol. Chem. 1994, 269, 12918–12924.
19. Wagner, E.; Plank, C.; Zatloukal, K.; Cotten,M.; Birnstiel, M. L.
Influenza Virus Hemagglutinin HA-2 N-Terminal Fuso-
genic Peptides Augment Gene Transfer by Transferrin-
Polylysine-DNA Complexes: Toward a Synthetic Virus-Like
Gene-Transfer Vehicle. Proc. Natl. Acad. Sci. U. S. A. 1992,
89, 7934–7938.
20. Meyer, M.; Dohmen, C.; Philipp, A.; Kiener, D.; Maiwald, G.;
Scheu, C.; Ogris, M.; Wagner, E. Synthesis and Biological
Evaluation of a Bioresponsive and Endosomolytic SiRNA-
Polymer Conjugate. Mol. Pharm. 2009, 6, 752–762.
21. Zuber, G.; Zammut-Italiano, L.; Dauty, E.; Behr, J. P. Tar-
geted Gene Delivery to Cancer Cells: Directed Assembly of
Nanometric DNA Particles Coated with Folic Acid. Angew.
Chem., Int. Ed. 2003, 42, 2666–2669.
22. Erbacher, P.; Remy, J. S.; Behr, J. P. Gene Transfer with
Synthetic Virus-Like Particles Via the Integrin-Mediated
Endocytosis Pathway. Gene Ther. 1999, 6, 138–145.
23. DeRouchey, J.; Walker, G. F.; Wagner, E.; Radler, J. O.
Decorated Rods: A “Bottom-Up” Self-Assembly of Mono-
molecular DNA Complexes. J. Phys. Chem. B 2006, 110,
4548–4554.
24. DeRouchey, J.; Schmidt, C.; Walker, G. F.; Koch, C.; Plank, C.;
Wagner, E.; Radler, J. O. Monomolecular Assembly of
SiRNA and Poly(Ethylene Glycol)-Peptide Copolymers.
Biomacromolecules 2008, 9, 724–732.
25. Akinc, A.; Goldberg, M.; Qin, J.; Dorkin, J. R.; Gamba-Vitalo,
C.; Maier, M.; Jayaprakash, K. N.; Jayaraman, M.; Rajeev,
K. G.; Manoharan, M.; et al. Development of Lipidoid-SiRNA
Formulations for Systemic Delivery to the Liver. Mol. Ther.
2009, 17, 872–879.
26. Hartmann, L.; Hafele, S.; Peschka-Suss, R.; Antonietti, M.;
Borner, H. G. Tailor-Made Poly(Amidoamine)s for Con-
trolled Complexation and Condensation of DNA. Chemis-
try 2008, 14, 2025–2033.
27. Schaffert, D.; Troiber, C.; Salcher, E. E.; Frohlich, T.; Martin, I.;
Badgujar, N.; Dohmen, C.; Edinger, D.; Klager, R.; Maiwald,
G.; et al. Solid-Phase Synthesis of Sequence-Defined T-,
I-, and U-Shape Polymers for pDNA and SiRNA Delivery.
Angew. Chem., Int. Ed. 2011, 50, 8986–8989.
28. Schaffert, D.; Badgujar, N.; Wagner, E. Novel Fmoc-Poly-
amino Acids for Solid-Phase Synthesis of Defined Poly-
amidoamines. Org. Lett. 2011, 13, 1586–1589.
29. Fröhlich, T.; Edinger, D.; Klager, R.; Troiber, C.; Salcher, E.;
Badgujar, N.; Martin, I.; Schaffert, D.; Cengizeroglu, A.;
Hadwiger, P.; et al. Structure-Activity Relationships of
SiRNA Carriers Based on Sequence-Defined Oligo (Ethane
Amino) Amides. J. Controlled Release 2012, 160, 532–541.
30. Wang, S.; Lee, R. J.; Mathias, C. J.; Green, M. A.; Low, P. S.
Synthesis, Purification, and Tumor Cell Uptake of 67Ga-
Deferoxamine--Folate, a Potential Radiopharmaceuti-
cal for Tumor Imaging. Bioconjugate Chem. 1996, 7,
56–62.
31. Boeckle, S.; von Gersdorff, K.; van der Piepen, S.; Culmsee,
C.; Wagner, E.; Ogris, M. Purification of Polyethylenimine
Polyplexes Highlights the Role of Free Polycations in Gene




DOHMEN ET AL . VOL. 6 ’ NO. 6 ’ 5198–5208 ’ 2012
www.acsnano.org
5208
32. Plank, C.; Mechtler, K.; Szoka, F. C., Jr.; Wagner, E. Activation
of the Complement System by Synthetic DNA Complexes:
A Potential Barrier for Intravenous Gene Delivery. Hum.
Gene Ther. 1996, 7, 1437–1446.
33. Hamad, I.; Al-Hanbali, O.; Hunter, A. C.; Rutt, K. J.; Andresen,
T. L.; Moghimi, S. M. Distinct Polymer Architecture Med-
iates Switching of Complement Activation Pathways at
the Nanosphere-Serum Interface: Implications for Stealth
Nanoparticle Engineering. ACS Nano 2010, 4, 6629–6638.
34. Kamen, B. A.; Capdevila, A. Receptor-Mediated Folate
Accumulation Is Regulated by the Cellular Folate Content.
Proc. Natl. Acad. Sci. U. S. A. 1986, 83, 5983–5987.
35. Xia, W.; Low, P. S. Folate-Targeted Therapies for Cancer.
J. Med. Chem. 2010, 53, 6811–6824.
36. Judge, A. D.; Robbins, M.; Tavakoli, I.; Levi, J.; Hu, L.; Fronda,
A.; Ambegia, E.; McClintock, K.; MacLachlan, I. Confirming
the RNAi-Mediated Mechanism of Action of SiRNA-Based
Cancer Therapeutics inMice. J. Clin. Invest. 2009, 119, 661–
673.
A
RTIC
LE
